6545 Using CRISPR-Cas13 as an antiviral for SARS-CoV-2 | Doherty Website

The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

Our Work | COVID-19

Antivirals and Virology

Using CRISPR-Cas13 as an antiviral for SARS-CoV-2

This discovery builds on research which started at Peter Mac in 2019 – when Dr Mohamed Fareh and Professor Joe Trapani showed a CRISPR gene editing tool could be used to eliminate abnormal RNAs that drive children’s cancers. In collaboration with Director Professor Sharon Lewin and Dr Wei Zhao from the Doherty Institute, this same approach has been shown to suppress replication of the RNA virus SARS-CoV-2 – and importantly its “variants of concern” – in a test tube model.

Project collaborators

Funders

  • Australian Department of Foreign Affairs and Trade
  • National Health and Medical Research Council
‹ Back to projects
0